THE MANAGEMENT OF EARLY DEGENERATIVE LESIONS

Abstract

Today several therapeutic options exist for the management of early degenerative lesions in the knee. These include marrow stimulation techniques (abrasion arthroplasty, sub-chondral drilling, microfracturing), periosteal and perichondral graft interposition, the implantation of synthetic matrices (collagen, carbon fibres, or glycosaminoglycan gel), autologous chondrocyte transplantation, osteochondral mosaic autografts or allografts, or simple arthroscopic lavage and debridement.

It appears that some of these techniques are moderately successful in the short-term, especially in younger patients with relatively recent localised chondral lesions or erosion, and in joints with normal stability and alignment. In these optimal conditions, it is possible to achieve repair in 70% of the diseased area. However, the cartilage remains substandard, with a one-third decrease in stiffness and increased tissue permeability.

In the early degenerative knee, conservative treatment options include unloader bracing and the use of chondroprotective agents. Unloader braces have been shown to improve the disease-specific quality of life and the functional status of patients with varus osteoarthritis in prospective randomised clinical trials. However, patients often find braces uncomfortable and of doubtful effectiveness.

Current information about the use of chondroprotective agents in the treatment of osteoarthritis suggests that intra-articular hyaluronic acid improves lubrication in the joint and helps to decrease swelling and inflammation. Used as dietary supplements, oral glucosamine and chondroitin sulphate appear to work synergistically together to cause a net increase in the amount of healthy articular cartilage, hereby slowing the progression of osteoarthritis. Convenient and safe, these intra-articular and oral chondroprotective agents present an exciting new approach in the treatment of early degenerative knee lesions.